1093 — CSPC Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$68.79bn
- HK$57.36bn
- CNY31.45bn
- 96
- 70
- 35
- 81
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22,103 | 24,942 | 27,867 | 30,937 | 31,450 |
Cost of Revenue | |||||
Gross Profit | 15,911 | 18,685 | 21,135 | 22,256 | 22,177 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17,503 | 18,552 | 21,035 | 23,314 | 23,981 |
Operating Profit | 4,600 | 6,390 | 6,832 | 7,623 | 7,469 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 4,626 | 6,391 | 6,847 | 7,582 | 7,389 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,733 | 5,229 | 5,688 | 6,232 | 6,073 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3,714 | 5,160 | 5,605 | 6,091 | 5,873 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,714 | 5,160 | 5,605 | 6,091 | 5,873 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.32 | 0.41 | 0.471 | 0.513 | 0.497 |
Dividends per Share |